• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

红细胞生成性原卟啉症中的肝脏疾病

Hepatic disease in erythropoietic protoporphyria.

作者信息

Bloomer J R, Phillips M J, Davidson D L, Klatskin G

出版信息

Am J Med. 1975 Jun;58(6):869-82. doi: 10.1016/0002-9343(75)90644-0.

DOI:10.1016/0002-9343(75)90644-0
PMID:1138541
Abstract

Two sisters had erythropoietic protoporphyria and a spectrum of liver disease. One (F.B.) died in hepatic failure within 3 months after the development of jaundice. Only 10 months before she died, she had exhibited only bromsulfalein retention and a borderline increase in serum transaminase. Surgical exploration because of the jaundice revealed patency of the bile ducts which was confirmed at autopsy. Wedge biopsy and autopsy specimens of liver showed an active cirrhosis with massive amounts of protoporphyrin in Kupffer cells, portal histiocytes, bile canaliculi and parenchymal cytoplasm. The other sister (L.R.) had never had symptomatic liver disease and only a slight increase in serum transaminase and bromsulfalein retention. On needle biopsy, the liver specimen showed portal inflammation with erosion of limiting plates, occasional bridging between triads and central areas of cell dropout. Protoporphyrin pigment was present in portal histiocytes, areas of central collapse and, more rarely, in parenchymal cytoplasm. These studies demonstrate that significant, progressive hepatic disease may occur insidiously in erythropoietic protoporphyria, and that once jaundice appears it may be followed rapidly by fatal hepatic failure.

摘要

两姐妹患有红细胞生成性原卟啉病及一系列肝脏疾病。其中一人(F.B.)在黄疸出现后3个月内死于肝功能衰竭。就在她去世前10个月,她仅表现出溴磺酚酞潴留及血清转氨酶轻度升高。因黄疸进行手术探查发现胆管通畅,尸检证实了这一点。肝脏楔形活检及尸检标本显示为活动性肝硬化,库普弗细胞、门脉组织细胞、胆小管及实质细胞质内有大量原卟啉。另一姐妹(L.R.)从未有过有症状的肝脏疾病,仅血清转氨酶轻度升高及溴磺酚酞潴留。肝穿刺活检显示门脉炎症伴界板侵蚀,偶尔汇管区与中央区之间有桥接及细胞脱失区。原卟啉色素存在于门脉组织细胞、中央塌陷区,较少见于实质细胞质内。这些研究表明,红细胞生成性原卟啉病可能隐匿地发生严重的进行性肝脏疾病,一旦出现黄疸,可能很快就会继以致命的肝功能衰竭。

相似文献

1
Hepatic disease in erythropoietic protoporphyria.红细胞生成性原卟啉症中的肝脏疾病
Am J Med. 1975 Jun;58(6):869-82. doi: 10.1016/0002-9343(75)90644-0.
2
An autopsy case of erythropoietic protoporphyria with cholestatic jaundice and hepatic failure, and a review of literature.一例伴有胆汁淤积性黄疸和肝衰竭的红细胞生成性原卟啉症尸检病例及文献复习
Virchows Arch A Pathol Anat Histol. 1981;393(2):123-32. doi: 10.1007/BF00431069.
3
Hepatic failure and death from erythropoietic protoporphyria.红细胞生成性原卟啉症导致的肝功能衰竭与死亡。
Gastroenterology. 1978 Mar;74(3):588-91.
4
Hepatic disease in erythropoietic protoporphyria.红细胞生成性原卟啉症中的肝脏疾病
Dermatologica. 1986;173(3):120-30. doi: 10.1159/000249233.
5
Early involvement of hepatic parenchymal cells in erythrohepatic protoporphyria? An ultrastructural study of patients with and without overt liver disease and the effect of chenodeoxycholic acid treatment.
Hepatology. 1990 Mar;11(3):449-57. doi: 10.1002/hep.1840110316.
6
Erythropoietic protoporphyria with hepatic cirrhosis.伴有肝硬化的红细胞生成性原卟啉症
Arch Dermatol. 1980 Apr;116(4):429-32.
7
Mouse model for protoporphyria. I. The liver and hepatic protoporphyrin crystals.
J Invest Dermatol. 1975 Sep;65(3):290-9. doi: 10.1111/1523-1747.ep12598357.
8
[Hepatic reactions in erythropoietic protoporphyria (author's transl)].红细胞生成性原卟啉症中的肝脏反应(作者译)
Virchows Arch B Cell Pathol Incl Mol Pathol. 1981;37(3):369-79.
9
[Liver transplantation in erythrohepatic protoporphyria].
Dtsch Med Wochenschr. 1992 Jul 10;117(28-29):1097-102. doi: 10.1055/s-2008-1062416.
10
Fatal liver failure in protoporphyria. Synergism between ethanol excess and the genetic defect.迟发性皮肤卟啉症中的致命性肝衰竭。乙醇过量与遗传缺陷之间的协同作用。
Gastroenterology. 1986 Jan;90(1):191-201.

引用本文的文献

1
The Histamine Pathway is a Target to Treat Hepatic Experimental Erythropoietic Protoporphyria.组胺途径是治疗肝脏实验性红细胞生成性原卟啉症的一个靶点。
Cell Mol Gastroenterol Hepatol. 2025;19(6):101463. doi: 10.1016/j.jcmgh.2025.101463. Epub 2025 Jan 15.
2
Management of erythropoietic protoporphyria with cholestatic liver disease: A case report.伴有胆汁淤积性肝病的红细胞生成性原卟啉病的管理:一例报告。
Mol Genet Metab Rep. 2023 Oct 31;37:101018. doi: 10.1016/j.ymgmr.2023.101018. eCollection 2023 Dec.
3
Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria.
阿法美拉肽与红细胞生成性原卟啉症相关肝损伤的剂量依赖性保护作用有关。
Life (Basel). 2023 Apr 21;13(4):1066. doi: 10.3390/life13041066.
4
Strong correlation of ferrochelatase enzymatic activity with Mitoferrin-1 mRNA in lymphoblasts of patients with protoporphyria.原卟啉原氧化酶活性与原卟啉原Ⅸ患者淋巴细胞中线粒体铁蛋白 1 mRNA 呈强相关性。
Mol Genet Metab. 2019 Nov;128(3):391-395. doi: 10.1016/j.ymgme.2018.10.005. Epub 2018 Oct 22.
5
Clinical, Biochemical, and Genetic Characterization of North American Patients With Erythropoietic Protoporphyria and X-linked Protoporphyria.北美红细胞生成性原卟啉症和X连锁原卟啉症患者的临床、生化及遗传学特征
JAMA Dermatol. 2017 Aug 1;153(8):789-796. doi: 10.1001/jamadermatol.2017.1557.
6
Iron-sulfur cluster biogenesis in mammalian cells: New insights into the molecular mechanisms of cluster delivery.哺乳动物细胞中的铁硫簇生物合成:簇传递分子机制的新见解
Biochim Biophys Acta. 2015 Jun;1853(6):1493-512. doi: 10.1016/j.bbamcr.2014.09.009. Epub 2014 Sep 19.
7
Abnormal mitoferrin-1 expression in patients with erythropoietic protoporphyria.红细胞生成性原卟啉症患者中线粒体铁蛋白 1 表达异常。
Exp Hematol. 2011 Jul;39(7):784-94. doi: 10.1016/j.exphem.2011.05.003. Epub 2011 May 11.
8
Theodore Woodward Award. Pathogenesis of biochemical abnormalities in protoporphyria.西奥多·伍德沃德奖。原卟啉症生化异常的发病机制。
Trans Am Clin Climatol Assoc. 2000;111:245-56; discussion 256-7.
9
Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation.需要进行肝移植的原卟啉症患者中铁螯合酶的分子缺陷。
J Clin Invest. 1998 Jul 1;102(1):107-14. doi: 10.1172/JCI1347.
10
Hepatic protoporphyrin metabolism in patients with advanced protoporphyric liver disease.晚期原卟啉性肝病患者的肝脏原卟啉代谢
Yale J Biol Med. 1997 Jul-Aug;70(4):323-30.